Join Growin Stock Community!

生達1720.TW Overview

TW StockBiotech. & Medical
(No presentation for 1720)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

生達(1720)Overall Performance

生達(1720)AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

生達(1720) PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

生達(1720)Key Information

生達(1720)Profile

Standard Chem & Pharm CO., LTD. engages in the manufacture and sale of pharmaceutical products, supplements, and APIs in Taiwan. It offers various pharmaceutical products, including circulatory system, digestive system, respiratory system, antihistamine, C.N.S, metabolism, anti-microbial, and skin and mucous membrane drugs, as well as human and veterinary APIs, and excipients. The company was founded in 1967 and is headquartered in Tainan City, Taiwan.

生達(1720)FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
5.19
PE Ratio (TTM)
12.27
Forward PE
11.71
PS Ratio (TTM)
1.62
PB Ratio
1.23
Price-to-FCF
9.20
METRIC
VALUE
vs. INDUSTRY
Gross Margin
41.42%
Net Margin
13.21%
Revenue Growth (YoY)
3.44%
Profit Growth (YoY)
-2.67%
3-Year Revenue Growth
4.09%
3-Year Profit Growth
2.59%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
5.19
PE Ratio (TTM)
12.27
Forward PE
11.71
PS Ratio (TTM)
1.62
PB Ratio
1.23
Price-to-FCF
9.20
Gross Margin
41.42%
Net Margin
13.21%
Revenue Growth (YoY)
3.44%
Profit Growth (YoY)
-2.67%
3-Year Revenue Growth
4.09%
3-Year Profit Growth
2.59%
default symbol

1720

生達

63.70D

-2.67%

(-0.03)

  • When is 1720's latest earnings report released?

    The most recent financial report for 生達 (1720) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 1720's short-term business performance and financial health. For the latest updates on 1720's earnings releases, visit this page regularly.

  • Where does 1720 fall in the P/E River chart?

    According to historical valuation range analysis, 生達 (1720)'s current price-to-earnings (P/E) ratio is 7.02, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of 1720?

    According to the latest financial report, 生達 (1720) reported an Operating Profit of 352.81M with an Operating Margin of 19.76% this period, representing a growth of 5.15% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 1720's revenue growth?

    In the latest financial report, 生達 (1720) announced revenue of 1.79B, with a Year-Over-Year growth rate of 6.71%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 1720 have?

    At the end of the period, 生達 (1720) held Total Cash and Cash Equivalents of 1.83B, accounting for 0.16 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 1720 go with three margins increasing?

    In the latest report, 生達 (1720) achieved the “three margins increasing” benchmark, with a gross margin of 41.22%%, operating margin of 19.76%%, and net margin of 17.64%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 1720's profit trajectory and future growth potential.

  • Is 1720's EPS continuing to grow?

    According to the past four quarterly reports, 生達 (1720)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.28. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 1720?

    生達 (1720)'s Free Cash Flow (FCF) for the period is 123.07M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 465.45% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.